Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system

References

• Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi: 10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Hou Z, Liu J, Jin Z, et al. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends. 2022;16(1):31–45. doi: 10.5582/bst.2022.01044
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(4):203–222. doi: 10.1038/s41575-022-00704-9
   PubMed Web of Science ®Google Scholar
• Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854. doi: 10.1056/NEJMra0904569
   PubMed Web of Science ®Google Scholar
• Durani U, Hogan WJ. Emergencies in haematology: tumour lysis syndrome. Br J Haematol. 2020;188(4):494–500. doi: 10.1111/bjh.16278
   PubMed Web of Science ®Google Scholar
• Chang H, Shih LY. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature. Chang Gung Med J. 2008;31(5):510–514.
   PubMedGoogle Scholar
• Constantinides M, Fayd’herbe De Maudave A, Potier-Cartereau M, et al. Direct cell death induced by CD20 monoclonal antibodies on B cell lymphoma cells revealed by new protocols of analysis. Cancers (Basel). 2023 [Published 2023 Feb 9];15(4):1109. doi: 10.3390/cancers15041109
   PubMed Web of Science ®Google Scholar
• Chou JW, Cheng KS, Akella T, et al. Tumor lysis syndrome in patients with hepatocellular carcinoma: a systematic review of published case reports. Cureus. 2021;13(10):e19128. doi: 10.7759/cureus.19128
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Sunagozaka H, Yamagata K, et al. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report. Clin J Gastroenterol. 2021;14(2):645–649. doi: 10.1007/s12328-020-01306-1
   PubMed Web of Science ®Google Scholar
• Goyal MK, Singh A, Kumar Gupta Y, et al. Lenvatinib-induced tumor lysis syndrome in advanced hepatocellular carcinoma. ACG Case Rep J. 2023 [Published 2023 Sep 5];10(9):e01139. doi: 10.14309/crj.0000000000001139
   PubMed Web of Science ®Google Scholar
• Raschi E, Poluzzi E, Salvo F, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28(6):533–542. doi: 10.1016/j.numecd.2018.02.014
   PubMed Web of Science ®Google Scholar
• Sarangdhar M, Tabar S, Schmidt C, et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol. 2016;34(7):697–700. doi: 10.1038/nbt.3623
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia. 2017;60(8):1385–1389. doi: 10.1007/s00125-017-4301-8d
   PubMed Web of Science ®Google Scholar
• Xia S, Gong H, Zhao Y, et al. Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: a pharmacovigilance study based on the FAERS database. Clin Pharmacol Ther. 2023;114(1):211–219. doi: 10.1002/cpt.2920
   PubMed Web of Science ®Google Scholar
• Khaleel MA, Khan AH, Ghadzi SMS, et al. A standardized dataset of a spontaneous adverse event reporting system. Healthcare. 2022;10(3):420. doi: 10.3390/healthcare10030420
   Web of Science ®Google Scholar
• Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519–523. doi: 10.1002/pds.1001
   PubMed Web of Science ®Google Scholar
• Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69. doi: 10.1177/0962280211403604
   PubMed Web of Science ®Google Scholar
• Raschi E, Fusaroli M, Ardizzoni A, et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186(1):219–227. doi: 10.1007/s10549-020-06001-w
   PubMed Web of Science ®Google Scholar
• Yang K, Li J, Sun Z, et al. Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors. Clin Exp Med. Published online Apr 4, 2023;23(7):3907–3918. doi: 10.1007/s10238-023-01055-8
   PubMed Web of Science ®Google Scholar
• Raschi E, Fusaroli M, Giunchi V, et al. Adrenal insufficiency with anticancer tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor: analysis of the FDA adverse event reporting system. Cancers (Basel). 2022;14(19):4610. doi: 10.3390/cancers14194610
   PubMed Web of Science ®Google Scholar
• Salter B, Burns I, Fuller K, et al. Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: a systemic review. Eur J Haematol. 2022;109(2):166–181. doi: 10.1111/ejh.13786
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema ADR, Schellens JHM, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507. doi: 10.2165/11531280-000000000-00000
   PubMed Web of Science ®Google Scholar
• Yan M, Li W, Li WB, et al. Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice. Drug Metab Rev. 2023;55(1–2):94–106.
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507. doi: 10.2165/11531280-000000000-00000
   PubMed Web of Science ®Google Scholar
• Berends AMA, van der Horst-Schrivers ANA, Oosting SF, et al. Hypocalcemia induced by tyrosine kinase inhibitors: targeted treatment with “untargeted” side effects. Acta Oncol. 2020;59(6):726–729. doi: 10.1080/0284186X.2020.1726455
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021;22(6):bbab347. doi: 10.1093/bib/bbab347
   PubMed Web of Science ®Google Scholar